We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Increased Immune Reaction Associated with Myeloproliferative Neoplasia

By LabMedica International staff writers
Posted on 03 Mar 2017
Print article
Image: Blood smear of a myeloproliferative neoplasia patient with a significant increase in the number of platelets (purple) as compared to the clearly larger red blood cells (Photo courtesy of Ed Uthman).
Image: Blood smear of a myeloproliferative neoplasia patient with a significant increase in the number of platelets (purple) as compared to the clearly larger red blood cells (Photo courtesy of Ed Uthman).
Patients afflicted by myeloproliferative neoplasia, which are a group of chronic malignant bone marrow diseases, bear a mutation in their hematopoietic stem cells. The mutation leads to the bone marrow producing too many blood cells, which thickens the blood.

It has recently discovered that certain cells of the immune system also bear this mutation in those patients that possess a particularly large number of altered stem cells. The impact of this scenario on the defense against pathogens has been investigated.

Scientists at Helmholtz Centre for Infection Research investigated patients with different severities of myeloproliferative neoplasia. The bone marrow harbors the hematopoietic stem cells that produce the various types of red and white blood cells and platelets. They are induced to do so by messenger substances that bind to them and trigger a reaction chain, in which many different components partake. In a rare malignant group of blood diseases called myeloproliferative neoplasia (MPN), most of the patients have hematopoietic stem cells that bear an error in their genetic material, known as a mutation.

The mutation usually resides in a certain component of the reaction chain called Janus kinase 2 (JAK2) and causes the signal for haematopoiesis to be permanently switched on in the stem cells. Depending on which type of stem cell is afflicted, the bone marrow of the patients produces the corresponding blood cells and the blood becomes too thick and may clog the vessels. MPN patients usually are treated with an inhibitor of JAK2 that suppresses the continuous signal triggering hematopoiesis. However, this also weakens the immune cells such that the patients become more susceptible to infections.

The scientists found that 60% of the patients, who have a particularly large number of damaged stem cells, bear the mutation in their so-called T cells as well. These cells of the immune system specifically fight against pathogens that entered the body. The scientists then infected mice with Listeria monocytogenes. Listeria bacteria colonize food items and can cause severe infections in humans including meningitis. When the scientists investigated the mice, they found: seven days after the infection with Listeria, the mice with the mutated T cells had 100-fold lower levels of bacteria in their spleen than the control mice. They had formed clearly more specific T cells directed against Listeria and were thus able to control the infection better than the control animals without a mutation in T cells.

Dirk Schlüter, MD, a professor and senior author of the study said, “It was previously unknown that so many MPN patients bear the mutation in their T cells as well. In order to find out what this actually means for the patients, we combined the clinical studies with studies on mice.” The study was published on January 11, 2017, in the journal Leukemia.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.